-
11.发明公开HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF 审中-公开HEPATITIS-B-VIRUSVARIANTEN MIT VERMINDERTER EMPFINDLICHKEITGEGENÜBERNUKLEOSIDANALOGEN UND VERWENDUNG DAVON
公开(公告)号：EP1499712A1
公开(公告)日：2005-01-26
申请号：EP03709442.2
申请日：2003-04-11
申请人： Melbourne Health , Austin Health , Southern Health
发明人： BARTHOLOMEUSZ, Angeline, Ingrid , LOCARNINI, Stephen, Alister , AYRES, Anna , COLLEDGE, Danielle , SASADEUSZ, Joseph,Melbourne Health , TILLMANN, Hans , ANGUS, Peter, William , SIEVERT, William,Department of Medicine
CPC分类号： C12Q1/6876 , C07K14/005 , C12N7/00 , C12N2730/10122
摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.
摘要翻译： 本发明涉及用于确定乙型肝炎病毒（HBV）的潜力的方法，所述变体表现出对阿德福韦酯，ADV和/或替诺福韦，TFV的敏感性降低。 本发明还涉及对ADV和/或TFV具有降低的敏感性的分离的HBV变体。 本发明进一步考虑了用于检测对这种病毒变体具有抑制活性的试剂的方法，以及这种病毒变体在抗HBV药物的合理设计中的用途以及用于制备用于治疗和/或预防HBV的药物 感染。
-
12.发明公开VIRAL VARIANTS WITH ALTERED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF 有权病毒，改变的灵敏度变体及其用途核苷
公开(公告)号：EP1476543A1
公开(公告)日：2004-11-17
申请号：EP03700697.0
申请日：2003-02-05
发明人： BARTHOLOMEUSZ, Angeline, Ingrid , LOCARNINI, Stephen, Alister , AYRES, Anna , ANGUS, Peter, William , SIEVERT, William,c/oMonash Medical Centre
CPC分类号： A61K39/0011 , A61K39/00 , A61K2039/505 , A61K2039/525 , A61K2039/53 , C07K14/005 , C12N7/00 , C12N9/1276 , C12N2710/14143 , C12N2730/10122 , C12Q1/706
摘要： The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for agents capable of inhibiting infection, replication and/or release of the virus.
-
搜索结果
12 条记录 (耗时 0.016 秒)
